Sign inJoin waitlistJoin the waitlist

Steven DuBois

, Director of · Mass General Brigham

Credentials: · · · · ·

History

St Jude Children's Research Hospital
Present

Pediatric Hematology Oncology
Boston Children's Hospital
2003–2006
Pediatrics
University of California (San Francisco) School of Medicine
2000–2003
University of California, San Francisco School of Medicine
1996–2000

Research

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
New England Journal of Medicine · 2018 · 2,193 citations
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
The Lancet Oncology · 2020 · 835 citations
Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
Journal of Clinical Oncology · 2016 · 488 citations

Katherine Matthay
72 papers
Katherine Janeway
55 papers · 1 as a fellow
David Shulman
36 papers · 2 as a fellow
Rochelle Bagatell
34 papers
Julie Park
27 papers
Brian Crompton
26 papers
Daphne Haas-Kogan
25 papers
JB
Julia Bender
24 papers
Robert Goldsby
24 papers
Kieuhoa Vo
21 papers
Alanna Church
20 papers
Holcombe Grier
19 papers

Grants

Tumor and Host Markers of Clinical Outcomes After MIBG Therapy in Neuroblastoma
National Cancer Institute · R01
Contact PI · $2.5M · Dana-Farber Cancer Inst
2018–2025
Optimizing 131I-mIBG Therapy for Children with Advanced Neuroblastoma
National Cancer Institute · R01
Contact PI · $1.6M · Dana-Farber Cancer Inst
2013–2020
PhI Trial of Dual PI3K/BRD4 Inhibitor SF1126 in Neuroblastoma IND124993 (12/2/14)
Food and Drug Administration · R01
Contact PI · $250K · Dana-Farber Cancer Inst
2017–2018
Bone Marrow Micrometastatic Disease in Ewing Sarcoma
National Cancer Institute · K23
Contact PI · $491.9K · University of California, San Francisco
2011–2014

Clinical trials

Pedi-STAR: Surface Target Antibody-drug Conjugate (ADC) Antigen Expression in Relapsed/Refractory Pediatric Solid and CNS Tumors
Principal investigator · Not yet recruiting
Dana-Farber Cancer Institute
2026–2030
Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma
Principal investigator · Recruiting · Phase 1
Steven DuBois, MD
2025–2027
Cabozantinib With Topotecan-Cyclophosphamide
Principal investigator · Completed · Phase 1
Dana-Farber Cancer Institute
2020–2022
Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer
Principal investigator · Completed · Phase 1
Dana-Farber Cancer Institute
2019–2024